全部 标题 作者
关键词 摘要

预印 - OALib 预印本无需同行审议


Powerful Efficacy of GCSB-5 Treatment for Improving Fatigue and Motor Function in Multiple Sclerosis (MS): A Randomized Double Blind, Place-bo-Controlled Study

DOI: 10.4236/oalib.preprints.1200150, PP. 1-10

Subject Areas: Psychology, Neuroscience

Keywords: Multiple Sclerosis, GCSB-5 Treatment

Full-Text   Cite this paper   Add to My Lib

Abstract

Multiple Sclerosis (MS) is the most common disability in young adults that requires early symptomatic treatment to prevent long-term disability. Among young adults, MS is the most common central nerv-ous system (CNS) chronic inflammatory illness that is characterized by demyelination in the CNS. However, current disease-modifying treatments are not sufficiently effective for preventing the variety of symptoms during the course of disease.

Cite this paper

Shin, J. Y. (2016). Powerful Efficacy of GCSB-5 Treatment for Improving Fatigue and Motor Function in Multiple Sclerosis (MS): A Randomized Double Blind, Place-bo-Controlled Study. Open Access Library PrePrints, 2, e150. doi: http://dx.doi.org/10.4236/oalib.preprints.1200150.

References

[1]  Barten, L. J., Allington, D. R., Procacci, K. A., Rivey, M. P., Barten, L. J., Allington, D. R., ... & Rivey, M. P. (2010). New approaches in the management of multiple sclerosis. Drug Design, De-velopment and Therapy, 4, 343.
[2]  Kim, E., Lovera, J., Schaben, L., Melara, J., Bourdette, D., & Whitham, R. (2010). Novel method for measurement of fatigue in multiple sclerosis: Real-Time Digital Fatigue Score. Journal of Re-habilitation Research & Development, 47(5).
[3]  McDonald, S., & Clements, J. N. (2011). Dalfampridine: a new agent for symptomatic manage-ment of multiple sclerosis. American Journal of Health-System Pharmacy, 68(24).
[4]  National Multiple Sclerosis Society (2014, May), Feys, P., Gijbels, D., Romberg, A., Santoyo, C., Gebara, B., de Noordhout, B. M., & Dalgas, U. (2012). Effect of time of day on walking capacity and self-reported fatigue in persons with multiple sclerosis: a multi-center trial. Multiple Sclerosis Journal, 18(3), 351-357.  Kennedy, P., & Hutchinson, C. B. Mobility in Multiple Sclerosis.
[5]  C.H. Polman, S.C. Reingold, G. Edan, M. Filippi, H.P. Hartung, L. Kappos. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Ann Neurol, 58, pp. 840–846 6
[6]  Abdanipour, A., Tiraihi, T., Taheri, T., & Kazemi, H. (2013). Microglial activation in rat experi-mental spinal cord injury model. Iranian Biomedical Journal, 17(4), 214-20.
[7]  Kim, E., Cameron, M., Lovera, J., Schaben, L., Bourdette, D., & Whitham, R. (2011). American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study. Multiple Sclerosis Journal, 17(12), 1523-1526.
[8]  Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mork, S., & Bo, L. (1998). Axonal tran-section in the lesions of multiple sclerosis. New England Journal of Medicine, 338(5), 278-285.
[9]  Kim, T. H., Yoon, S. J., Lee, W. C., Kim, J. K., Shin, J., Lee, S., & Lee, S. M. (2011). Protective effect of GCSB-5, an herbal preparation, against peripheral nerve injury in rats. Journal of Eth-nopharmacology, 136,2, 297-304. 
[10]  Multiple Sclerosis Foundation (2009, July) Retrieved from http://www.msfocus.org/Retrieved from http://www.nationalmssociety.org/What-is-MS/Who-Gets-MS#section-0
[11]  Pender, M. P., Csurhes, P. A., Houghten, R. A., McCombe, P. A., & Good, M. F. (1996). A study of human T-cell lines generated from multiple sclerosis patients and controls by stimulation with peptides of myelin basic protein. Journal of neuroimmunology, 70(1), 65-74.
[12]  Snook, E. M., & Motl, R. W. (2009). Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis. Neurorehabilitation and neural repair, 23(2), 108-116.
[13]  Chung, H. J., Lee, H. S., Shin, J. S., Lee, S. H., Park, B. M., Youn, Y. S., & Lee, S. K. (2010). Modulation of acute and chronic inflammatory processes by a traditional medicine preparation GCSB-5 both in vitro and in vivo animal models. Journal of ethnopharmacology, 130,3), 450-459.
[14]  Ruck, T., Bittner, S., Simon, O. J., Gobel, K., Wiendl, H., Schilling, M., & Meuth, S. G. (2013). Long-term effects of dalfampridine in patients with multiple sclerosis. Journal of the neurological sciences.

Full-Text


comments powered by Disqus